Do We Need More Medical Tests as We Get Older — or Fewer?

Check your blood pressure. Check your cholesterol. Attend your cancer screening. Have your vaccinations. Take preventive medicines when they are appropriate.

For much of adult life, the message is simple: do not ignore prevention.

It is a good message. But eventually another question becomes important:

Does every preventive test and treatment remain equally useful at every age?

No. That does not mean healthcare stops mattering as we get older. Quite the opposite. It means good healthcare may need to become more individual.

The test itself is not the benefit

Finding something earlier helps only when finding it earlier is likely to improve an outcome that matters. Screening can detect disease before symptoms, enable earlier treatment and reduce illness or deaths from some conditions. It can also lead to false-positive results, anxiety, repeat tests, scans, biopsies, treatment side effects and overdiagnosis.

Overdiagnosis does not necessarily mean the diagnosis is wrong. It can mean finding a real abnormality or disease that would never have caused symptoms or shortened that person's life. Because we cannot always know that at the beginning, screening decisions involve probabilities rather than guarantees.

Finding more disease is not automatically the same as creating more health.

Why age changes the equation

This is not an argument that older people are less worthy of care. It is an argument for care that reflects the person rather than a birthday alone.

The balance of benefit and harm can change with a person's chance of developing the disease, other medical conditions, frailty, functional capacity, likely response to treatment, treatment burdens, personal priorities and the time before an intervention is expected to help.

A healthy, independent person in their late seventies may have very different circumstances from somebody of exactly the same age living with severe frailty and several serious illnesses.

Age is part of the story. It is not the whole story.

Example one: bowel cancer screening

Bowel screening uses a faecal immunochemical test (FIT). You take a small stool sample at home and send it for testing. FIT looks for tiny amounts of blood, which can be a sign of bowel cancer or another condition.

A positive screening result is not a cancer diagnosis. It means further assessment is needed, which may include colonoscopy. Colonoscopy can find cancers and polyps, but it is still an invasive procedure with burdens and risks. A person's health and ability to undergo investigation or treatment therefore matter to the overall decision.

The message is not “stop bowel screening”. It is: understand what the test is for, what a result could lead to and what the current programme offers you.

Example two: breast screening

Mammography can detect breast cancer before symptoms develop. It can also produce false-positive results, additional imaging, biopsy and overdiagnosis, including treatment of a cancer that might never have become clinically significant.

In England, routine NHS breast-screening invitations are generally sent every three years from age 50 up to a person's 71st birthday; people aged 71 or over can contact their local service to request screening. Scotland routinely offers screening every three years to women aged 50 to 70, with self-referral available from 71. Wales invites women from age 50 up to their 70th birthday, normally every three years, and allows those aged 70 or over to request an appointment. Northern Ireland routinely invites women aged 50 to 70 every three years.

Example three: PSA testing

The UK does not currently have a national population-screening programme for prostate cancer using the prostate-specific antigen, or PSA, test. Men can discuss the test with their GP and make an informed decision using current NHS guidance.

A raised PSA can occur for reasons other than cancer. Testing may lead to repeat blood tests, MRI, biopsy, diagnosis and treatment. Some prostate cancers are aggressive and matter greatly. Others grow slowly and may never cause harm during a person's lifetime.

The issue is not “PSA good” versus “PSA bad”. Better questions are: what is my individual risk, what might the result lead to, and would knowing help me make a better decision?

What about statins?

Statins are preventive treatment rather than screening. They reduce cardiovascular risk for appropriate people, including many older adults. NICE guidance covers their use for people at risk of cardiovascular disease and for people who already have cardiovascular disease.

Do not treat age as an automatic reason to stop. A medication review may consider existing cardiovascular disease, overall risk, frailty, other medicines, side effects, interactions and the person's priorities.

Do not stop a prescribed statin abruptly because of this article. If you wonder whether a long-standing medicine remains appropriate, discuss it with your GP, pharmacist or prescribing clinician.

And aspirin?

Aspirin illustrates why the reason for a medicine matters. Somebody who has already had certain cardiovascular events or disease may be prescribed antiplatelet treatment for a clear secondary-prevention purpose.

That is different from taking aspirin independently in the hope of preventing a first heart attack or stroke. Aspirin can cause bleeding. NICE says aspirin should not routinely be offered for primary prevention of cardiovascular disease.

Do not start aspirin as a generic longevity strategy. If aspirin has been prescribed, discuss any proposed change with a healthcare professional rather than stopping it yourself.

Why does the NHS not screen everyone forever?

A population-screening programme is more than a test. It is a pathway involving invitations, testing, further investigation, diagnosis and treatment. The UK National Screening Committee says the whole pathway should do more good than harm at reasonable cost.

That means asking whether the condition is important, the test is accurate enough, earlier detection improves outcomes, effective treatment exists, harms are acceptable and the programme produces an overall benefit. The ability to detect an abnormality is only one part of the decision.

The time-to-benefit idea

Some preventive interventions help relatively quickly. Others may take years before their statistical benefits become apparent. When an intervention carries immediate burdens or risks but its likely benefit lies further ahead, overall health and personal priorities become relevant.

This is sometimes called time to benefit. It is not a DIY life-expectancy calculation, and older age alone does not mean there is insufficient time to benefit. It is one concept for a shared clinical conversation.

More testing can create a cascade

Sometimes that cascade saves a life. Sometimes it finds something that would never have caused harm. Sometimes it produces complications, cost and anxiety. The difficult part is that we do not always know which path we are on at the beginning.

Do not swing too far the other way

The lesson is not “stop getting tested when you are old”. Many preventive interventions remain valuable in later life: blood-pressure detection and treatment, vaccination, diabetes and cardiovascular-risk management, osteoporosis assessment for appropriate people, eye and hearing checks, medication reviews and appropriate cancer screening.

Right care. Right person. Right time.

Five questions worth asking

These questions support a conversation with a healthcare professional. They are not a DIY framework for refusing medically indicated investigation.

Apply the Age Watchers framework

Do not just ask “What tests am I due?”

A word about private health checks

Full-body MRI, CT scans, large blood panels, tumour-marker panels, genetic tests, biological-age tests and advanced cardiovascular screening are increasingly available to buy. They are not universally bad. But the ability to buy a test does not mean it is recommended for population screening.

Potential problems include false positives, incidental findings, uncertain significance, follow-up procedures, anxiety and cost. Ask what evidence supports testing someone like you, what happens after an unclear result and who takes clinical responsibility for follow-up.

Age Watchers is pro-measurement. We are not pro-testing for the sake of testing.

Age Watchers is not your doctor

Age Watchers can help you understand measurements, record trends, learn about prevention, prepare questions and build healthy habits. It cannot decide whether you should stop screening or medication, whether symptoms are harmless, or whether treatment is unnecessary. Those decisions require an appropriate healthcare professional.

The question that matters

For decades we are told: check it, screen it, prevent it. That is generally excellent advice. Healthy ageing adds nuance.

Sometimes the right question is not “Can we test for this?” It is:

Will knowing this improve what happens next?

Good healthcare is not measured by the number of tests we accumulate. It is measured by whether care helps us live healthier, more capable lives.

Measure useful things.
Understand what they mean.
Improve what you can.
Keep reviewing what still makes sense.

MEASURE. UNDERSTAND. IMPROVE. MAINTAIN.

Sources / Further reading

• UK National Screening Committee: principles of population screening.
• GOV.UK: screening programmes across the UK.
• NHS: bowel cancer screening.
• NHS inform: bowel screening in Scotland.
• Public Health Wales: bowel screening.
• nidirect: bowel cancer screening.
• NHS: breast screening.
• NHS inform: breast screening in Scotland.
• Public Health Wales: breast screening.
• nidirect: breast screening.
• NHS: PSA testing.
• NICE NG238: cardiovascular disease risk assessment and lipid modification.